Vardenafil Dihydrochloride tractans erectile dysfunction 224785-91-5

Pharmacological actio
Hoc pharmacum est phosphodiisterstere type V (PDE5) inhibitor. Oral administrationem huius medicamento potest efficaciter amplio qualitas et duratione erectionem, et amplio victoria rate of sexualem vitae in masculum aegris cum erectile distemperantia. Initiatio et sustentationem de Penile erectione est ad relaxationem in cavernosi lenis musculus cellulis et cyclic guanosine monophosphate (CGMP) est mediator est relaxationem de cavernosal lenis musculus cellulis. Hoc medicamento prohibet corrumpuntur CGMP per inhibens Phosphodiisterase Type V, ita causando cumulus CGMP, ad relaxationem lenis musculus de Corpus Cavmp, et relaxationem lenis musculus in corpus capvernosum et erectionem penis. Comparari cum phosphodiisterase Isozymes I, II, III, IV et VI, hoc medicamento habet princeps selectivity ad genus V phosphodiesterase. Quidam notitia ostendere quod eius selectivity et inhibitory effectus in phosphodiisterse type V sunt melius quam alia phosphodiesterase genus V inhibitors. Typus phosphodiesterase inhibitors sunt pauci.

Medicinales proprietatibus et applications

1. When used together with CYP 3A4 inhibitors (such as ritonavir, indinavir, saquinavir, ketoconazole, itraconazole, erythromycin, etc.), it can inhibit the metabolism of this drug in the liver , it increases the plasma concentration, prolongs the half-life, and increases the incidence of adverse reactions (such as hypotension, Visual mutationes, capitis, facialis rutilant, priapism). Hoc medicamento vitanda est cum Ritonavir et Indinavir. Cum usus est in tandem cum Erythromycin, Ketoconazole et itraconazole, maximam dose huius medicamento non excedunt V mg, et dose ketoconazole et itraconazole non excedunt CC mg.
II. Aegros taking nitrates aut accepto nitric cadmiae donor therapy debet vitare usura is medicamento in iunctura. Et mechanism de actione est adhuc crescatConcentration CGMP, unde in amplificata antihypertensive effectus et auctus cor rate. Cum usus una cum α-receptor blockers, quod potest augendae antihypertensive effectus et ducunt hypotension. Ideo usum huius medicamento prohibetur illis qui per α-receptor blockers. A medium-fat diet (30% of fat calories) had no significant effect on the pharmacokinetics of a single oral dose of 20 mg of this drug, and a high-fat diet (more than 55% of fat calories) could prolong the peak time of this drug and reduce the blood concentration of this drug The peak is about 18%.

Pharmacokinetics
Est cursim absorbetur post oris administratione, absoluta bioavailability de oris Tablet est XV% et mediocris ad apicem est 1 (0.5-2h). Oral solutio 10mg vel 20mg, in average apicem tempus est 0,9h et 0,7h, in mediocris apicem plasma concentration est 9μg / l et 21μg / l, respectively et duratio medicamento effectus potest pervenire 1. In dapibus binding rate huius medicamento est de XCV%. 1.5H post unum oralis dose of XX mg, in medicamento contentus in semen est 0.00018% of the dose. Medicamento est maxime metabolized in iecoris per Cytochrome P450 (CYP) 3A4 et parva moles est metabolized per Cyp 3A5 et Cyp 2c9 Isoenzymes. Pelagus metabolite est M1 formatae ab deethylation Piperazine structuram huius medicamento. M1 quoque habet effectus inhibendi phosphodiisterstere V (circiter VII% of totalis efficaciam) et sanguinem concentration est de XXVI% de parente sanguine concentration. , Et potest esse amplius metabolized. In excretion rates of pharmaca in forma metabolitarum in feces et urina sunt circa XCI% ad XCV% et II% ad VI%, respectively. In altiore alvi rate est LVI l per hora, et dimidium-vitas parentis compositis et M1 et de IV ad V horas.